Preclinical CRO services to explore Tumor-Associated-Macrophages (TAM) as a key driver of Cancer
Tumor-Associated Macrophages (TAMs) play an important role in tumor development, modulation of neoangiogenesis, immune suppression, and metastasis. A high infiltration of macrophages in the tumor is often correlated with a poor prognosis in several types of cancer. Therefore, they became an attractive target for cancer immunotherapies.
Several macrophage-targeting approaches in anticancer therapy are under development, including TAM depletion, inhibition of new TAM differentiation, or re-education of TAM activation for cancer cell phagocytosis.
Oncodesign Services offers a comprehensive preclinical platform to explore Macrophages
To facilitate your TAM-related research, we designed at Oncodesign Services a comprehensive preclinical platform to better evaluate and support the preclinical development of novel TAM-targeting therapies using this toolbox.
In order to better evaluate and support the pre-clinical development of novel TAM-targeting strategies, we implemented a large panel of in vitro assays and in vivo models:
-
In vitro ODS assays
- Antibody-dependent cellular phagocytosis (ADCP) assay
- M2 polarization inhibition assay
(non-exhaustive list)
-
In vivo ODS models
- Syngeneic mouse models: PAN02, Renca, Hepa1-6 to evaluate anti-CSF1R antibodies or demonstrate immunosuppressive reprogramming into an M1 phenotype
- Humanized mouse models: breast, colon, head & neck, and melanoma PDX and CDX tumors in different huCD34-engrafted mouse models to assess TAM-mediated antitumor activity of compounds displaying no cross reactivity with murine target
(non-exhaustive list)
Oncodesign Services is pleased to help you in preclinical evaluation of your TAM-targeting therapies. Please feel free to contact us, our team is at your disposal at any time.
